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A B S T R A C T
The development and spread of bacterial resistance to antimicrobial drugs necessitates the need to search for
novel and eﬀective antimicrobial agents. In the last few decades, innovative nanomaterials are attracting in-
creasing attention and, among them, dendrimers have shown wide application in the various ﬁelds. In the
current study, the two generations of an anionic linear- spherical nanodendrimer G1 and G2 were synthetized
and compound G2 of nanodendrimer conjugated with erythromycin. The structures of the nanodendrimers were
characterized by FTIR spectroscopy, zetasizer, and scanning electron microscopy (SEM). The antibacterial ac-
tivity of the erythromycin-conjugated nanodendrimer and erythromycin alone were evaluated by the micro-
dilution method against Staphylococcus aureus, S. epidermidis, S. saprophyticus, and Pseudomonas aeruginosa. The
size of ﬁrst and second generation of nanodendrimer, and the erythromycin-conjugated nanodendrimer was 75,
95, and 65.6 nm, respectively. The drug loading percentage of the nanodendrimer conjugates was obtained to be
in 35.2%. In our study, the erythromycin-conjugated nanodendrimer showed signiﬁcantly more bacteriostatic
and bactericidal activities against all four studied bacteria than erythromycin alone. Our study's results highlight
that the erythromycin-conjugated nanodendrimer is a highly eﬀective agent against Gram positive and negative
bacteria. The antibacterial properties of erythromycin combined with the targeting potential of the nanoden-
drimer can lead to sustained intracellular delivery of therapeutic agent.
1. Introduction
Bacteria are common infective agents producing a wide variety of
diseases. Today, treatment of bacterial infections due to the emergence
of new infectious agents and increasing the number of drug-resistant
pathogens has been still stayed as an important problem. The emer-
gence of resistant bacterial pathogens occurred in other times by the
intensive and incorrect use of antimicrobial agents (Ghosh et al., 2018;
Tabatabaei et al., 2017; Tanwar et al., 2014). In recent years, many
studies have focused on developing novel and eﬀective antimicrobial
agents. Additionally, the goal of successful medical treatment is de-
livery of a proper concentration of drug to the proper location so as to
achieve the most eﬀective therapeutic and lowest toxicity (Chatterjee
et al., 2008; Moritz and Geszke-Moritz, 2013).
Most recently using the new technologies of human knowledge has
been signiﬁcantly considered in the medical and medicinal ﬁelds.
Meanwhile, nano-technology has opened a new era in front of
researchers' eyes. The ﬁeld of nanomedicine is emerging as nanosys-
tems enable scientists to enhance more favorable pharmacodynamics
and pharmacokinetic properties and can even be used in combination
with traditional drugs (Authimoolam and Dziubla, 2016; Biswas et al.,
2014). The dendrimers are one of the most important nanostructures
investigated in the ﬁeld of nanomedicine that have served as a unique
platform for drug delivery. These nanomaterials are made of a central
core, derived units as branches, and superﬁcial groups (Abbasi et al.,
2014; Jain and Asthana, 2007). The unique characteristics of dendrimer
structure are its heavy-branched and regular structure, terminal multi-
active groups and the empty cavities between the branches. These
empty spaces have ability of accepting the guest molecules in various
sizes (Charles et al., 2012; Strydom et al., 2013).
Erythromycin is used as a macrolide in treatment of many bacterial
infections. Unfortunately, the emergence of resistance to these anti-
biotics in recent years has become an increasing health concern
worldwide. The use of nanodendrimer in combination with traditional
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antimicrobial agents such as erythromycin can increase its therapeutic
eﬀects. Furthermore, conjugation of poorly water-soluble drugs to the
soluble nanodendrimer can increase the bioavailability as well as drug
solubility (Bosnjakovic et al., 2011; Jelić and Antolović, 2016; Tulu
et al., 2009).
Given the importance of using nanoparticles in the treatment of
infectious diseases, the need for study is more than ever. Therefore, the
aim of this study was to synthesis of the erythromycin-conjugated na-
nodendrimer and evaluation of its antibacterial activity.
2. Materials and methods
2.1. Material and bacterial isolates
Poly(ethylene glycol) methyl ether (m-PEG), dicyclohex-
ylcarbodiimide (DCC), ethyl dimethylaminopropyl carboxamide (EDC),
dimethyl sulfoxide (DMSO) and erythromycin were obtained from
Sigma (Sigma-Aldrich, MO, USA). Four standard strains of bacteria
were purchased from Pasteur Institute (Tehran, Iran).
2.2. Synthesis of the ﬁrst (G1) and second generation (G2) nanodendrimer
In the present study, the anionic linear-globular nanodendrimers G1
and G2 (having PEG core and citric acid periphery surface) were syn-
thetized according to Namazi and et al. method with a few modiﬁcation
(Namazi and Adeli, 2003).
Synthesis of compound G1 of nanodendrimer was initiated through
adding 2mL of PEG-600 as a dendrimer core to the Dried DMSO. DMSO
worked as a basis of the reaction. Then 1.8 g of DCC was added and
mixed for 5min in the condition of darkness and vacuum. DCC acti-
vated PEG by substitution with hydrogen atom of carboxylic acid
groups. Finally, 1.7 g citric acid was added to the solution and within
30min, the color of the tick solution changed to orange with stench.
Reaction was terminated with adding water and after ﬁltration; yellow-
brown solution of nanodendrimer was obtained. The product of G1 was
separated and puriﬁed by dialysis. Pore size of dialysis bag was 500 Da.
Since the presence of impurity could interact with the next step of
synthesis, so the column chromatography used as a puriﬁcation
method. Then the samples were lyophilized for DMSO removal.
To synthesize nanodendrimer G2, 500mg DCC was added to 310mg
solution of nanodendrimer G1 in DMSO and stirred for at least 15min
and thereafter yellow-brown color was appeared. In the next stage, 1 g
citric acid was added and after 30min, 500mg DCC was repeatedly
added to the solution and stirred for 4 days at room temperature. The
change in the color of the solution to dark cream veriﬁed the synthesis
of the G2 nanodendrimer. As synthesis of the nanodendrimer, reaction
was terminated with water addition, solution was ﬁltrated, dialyzed
(pore size of 1000 Da), passed through the column chromatography
process, and powder was lyophilized.
2.2.1. Conﬁdence of G1 and G2 synthesis
Fourier Transform Infrared (FTIR) analysis was carried out to con-
ﬁrm the structure of G1 and G2 nanodendrimers. Size and electric
charge of the nanodendrimers was determined by zetasizer (dynamic
light scattering, DLS).
2.3. Preparation of erythromycin-nanodendrimer conjugates
Tendency of erythromycin to the activated carboxyl groups of na-
nodendrimer leads to the reaction and incorporation of erythromycin
into the nanodendrimers. First the G2 lyophilized dendrimer and DCC
or EDC were stirred for at least 15min to activate functional groups of
G2 to make it ready for conjugation with erythromycin. After that,
500mg erythromycin was added to activate nanodendrimer and was
stirred for 7 days. Chromatography lyophilization was used as the
previous step to yield purity.
2.3.1. Conﬁdence of erythromycin conjugation
FTIR and scanning electron microscopy (SEM) analysis was carried
out to conﬁrm the structure and morphology of erythromycin-nano-
dendrimer conjugates, and zetasizer was used to determine the charge
and size.
2.3.2. Determination of drug loading
Drug loading was determined following the indirect method (free
drug concentration in supernatant). Percentage of drug loading was
evaluated by determining the amount of free erythromycin in the ery-
thromycin-nanodendrimer conjugate solution which was separated by
using the cooling centrifuge (12,000 rpm for 20min at 4 °C). The con-
centration of erythromycin in the supernatant was determined using
UV–visible spectrophotometer at 280 nm. The drug loading were cal-
culated by the following equations:
=
×
Drug loading efficiency (weight of loaded drug in nanodendrimer
/weight of feeding drug) 100%.
2.4. Antibacterial activity assay
In the present study, the antibacterial activity of the erythromycin-
conjugated nanodendrimer and erythromycin alone were evaluated
against Staphylococcus aureus ATCC 29213, S. epidermidis ATCC 12228,
S. saprophyticus ATCC 15305, and Pseudomonas aeruginosa ATCC 27853.
For this, two antimicrobial assays including the minimum inhibitory
concentration (MIC) assay and the minimum bactericidal concentration
(MBC) assay were applied.
2.4.1. Determination of the minimum inhibitory concentration (MIC)
The MICs were determined by the broth microdilution method and
interpreted using the Clinical and Laboratory Standards Institute (CLSI)
guidelines (Wayne, 2004). Brieﬂy, Mueller Hinton broth (Becton
Dickinson, USA) containing two-fold concentration increments of an-
timicrobial agents were added to 96-well microdilution plates. Test
organism suspension equal to a 0.5 McFarland standard was further
diluted and added to the plates to achieve a ﬁnal inoculum of
5×105 CFU/mL. The plates were incubated for 18–20 h at 37 °C in
ambient air. Media containing bacteria alone was used as positive
control. Noteworthy, this procedure was repeated three times. The MIC
was deﬁned as the lowest agent concentration at which observable
growth was inhibited.
2.4.2. Determination of the minimum bactericidal concentration (MBC)
The minimum bactericidal concentration (MBC) was also assessed
according to the CLSI guidelines (Wayne, 2004). In brief, after com-
pletion of the MIC assay, 10 μL from each clear well containing test
compounds was subcultured to Mueller Hinton agar (Becton Dickinson,
USA). The plates were incubated for 24 h at 37 °C in ambient air. The
colony forming units (CFU) were determined visually. The MBC was
taken as the concentration at which a three-log decrease in bacterial
growth (> 99.9%) was detected compared to the initial inoculum.
Experiments were performed in triplicate.
3. Results
3.1. Characterization of nanodendrimers
The sizes and zeta potential distributions of the nanodendrimers and
erythromycin-conjugated nanodendrimer in concentration of 0.1mg/
ml were measured by DLS (Figs. 1 and 2). The G1 nanodendrimer size
was obtained 326 nm for the ﬁrst time but this size is unreal and so big
and represents the aggregation of dendrimers together. After preparing
a more diluted sample and 20min of sonication, the particles size was
determined 75 nm. However, this problem was resolved for G2
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nanodendrimer and the particle size was about 91 nm. Furthermore,
size of erythromycin-conjugated G2 nanodendrimer was obtained about
65.6 nm. It is noteworthy that the surface charge of nanodendrimer G1,
G2 and the erythromycin-conjugated nanodendrimer was −5.7, −3.3
and +5.2mV, respectively.
Moreover, the morphology and size of the erythromycin-conjugated
nanodendrimer was characterized using SEM. The SEM image of ery-
thromycin-conjugated nanodendrimer clearly showed the spherical
dendrimer in diﬀerent sizes (Fig. 3). Generally, the mean nanoden-
drimer size which was obtained by DLS was larger than that determined
by SEM. This diﬀerence is due to aggregation of the nanodendrimer in
aqueous solutions.
3.2. FTIR spectroscopy
FTIR spectroscopy was used to determine the structure of the
G2 nanodendrimer
Erythromycin-conjugated G2 nanodendrimer
G1 nanodendrimer
Fig. 1. Particle size of the nanodendrimers.
Fig. 2. Zeta potential of the nanodendrimers.
F. Fallah et al. European Journal of Pharmaceutical Sciences 123 (2018) 321–326
323
synthetized products. FTIR spectrum of G1 nanodendrimer is shown in
Fig. 4. The observed peak in 1279 cm−1 is related to CeO groups that
conﬁrmed the formation of the ester bond between PEG and citric acid,
so represents the synthesis of G1 nanodendrimer. The 1154–1279 cm−1
range shows alcoholic CeO in PEG and citric acid. A broad peak at
3200–3500 cm−1 is related to the vibration of OeH bond.
In FTIR spectrum of G2 nanodendrimer (Fig. 4), the 1232 cm−1
peak shows CeO group that conﬁrms the formation of the ester bond
between terminal groups of G1 dendrimer and new citric acid groups,
and G2 nanodendrimer synthesis. Also a broad peak observed at
2500–3430 cm−1 which is related to acidic OH in citric acid.
Finally, in FTIR spectrum of erythromycin-conjugated G2 nano-
dendrimer (Fig. 4), a broad peak observed at 1022–1196 cm−1 is re-
lated to CeO groups that conﬁrmed the formation of the ester bond
between nanodendrimer carboxyl groups and erythromycin, so re-
presents the synthesis of erythromycin-conjugated nanodendrimer.
Furthermore, the 1351 cm−1 peak is for CeO groups in the ery-
thromycin. The broad peak at 3200–3405 cm−1 is assigned to the vi-
bration bonds of OH in erythromycin. The peak around 1724 cm−1
attributed to C]O bond in the nanodendrimer.
3.3. Percentage drug loading of erythromycin-conjugated nanodendrimer
The drug loading percentage of the erythromycin-conjugated na-
nodendrimer was obtained to be in 35.2%.
3.4. Antibacterial activity assay
In this study, the in-vitro antibacterial activity of the erythromycin-
conjugated nanodendrimer was evaluated against both Gram-negative
(P. aeruginosa) and Gram-positive (S. aureus, S. epidermidis, and S. sa-
prophyticus) bacteria. The MICs and MBCs erythromycin alone and the
erythromycin-conjugated nanodendrimer against the bacteria studied
are shown in Table 1. The results indicated that the erythromycin-
conjugated nanodendrimer was 2- to 16-fold more active than ery-
thromycin against the bacteria. The most antimicrobial activity of the
nanodendrimer was observed against S. saprophyticus.
4. Discussion
In recent years nanometric polymeric carriers have been extensively
used for drug and gene delivery. Meanwhile, dendrimers has gained
Fig. 3. SEM image of erythromycin-conjugated nanodendrimer.
Fig. 4. FTIR spectra the nanodendrimers.
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popularity in last two decades due to their stability, nanoscale size,
multifunctionality, biodegradable nature and non-immunogenic char-
acteristics. Furthermore, the unique structural feature of dendrimers is
their regular branched structure, and the empty cavities between the
branches that this space has ability of accepting guest molecules in
diﬀerent sizes (Bosnjakovic et al., 2011; Jain and Asthana, 2007;
Strydom et al., 2013).
In the present study, the anionic linear-globular nanodendrimers
containing citric acid and PEG as the core were synthetized according to
Namazi and et al. method (Namazi and Adeli, 2003). The sizes of the
nanodendrimers G1 and G2 were 75 and 91 nm, respectively. The
synthesis of the nanodendrimers and the presence of functional groups
could be conﬁrmed using diﬀerent methods including FTIR spectro-
scopy. FTIR analysis conﬁrmed that the nanodendrimers G1 and G2
were synthesized, owing to typical peaks of CeO group such as 1279
and 1232 cm−1 which are attributed to the formation of the ester bond
between PEG and citric acid and between terminal groups of G1 den-
drimer and new citric acid groups. The nanodendrimers synthesized in
this study are in the nano-scale and have not been reported any toxicity
and immunological eﬀects for them. Furthermore, these compounds are
biocompatible. Because PEG which used as the core in the dendrimers
and citric acid as the dendrimer branches are biocompatible, as well as
citric acid is an intermediate compound in metabolic pathways (Akram,
2014; Twibanire and Grindley, 2014). It is noteworthy that in the
dendrimer synthesis method in this study, not only used much less
toxicity compounds but also reduced the reaction time. In the study,
DCC was used instead of chlorinated compounds such as di-
chloromethane that are commonly used in the synthetic reactions as
activator components. The chlorinated compounds are very toxic and
can damage the human respiratory system (Henschler, 1994).
The dendrimer G2 synthesized in the present study is completely
soluble in water, so it is a good candidate to increase solubility of the
insoluble drugs in water. In the study, erythromycin was conjugated
with the nanodendrimer G2. FTIR analysis conﬁrmed that the ery-
thromycin-conjugated nanodendrimer was synthesized, having typical
peaks of CeO groups at 1022–1196 cm−1 range which are attributed to
the formation of the ester bond between nanodendrimer carboxyl
groups and erythromycin. Moreover, the nanodendrimer conjugate had
a slightly positive zeta potential (5.2 mV) compered than the nano-
dendrimer G2 (−3.3mV), which is due to the bonding of the positively
charged erythromycin to superﬁcial carboxyl groups of the nanoden-
drimer.
Finally, in this study the antibacterial activity of the erythromycin-
conjugated nanodendrimer was evaluated against Gram positive and
-negative bacteria. The results indicated that the erythromycin-con-
jugated nanodendrimer was 2- to 16-fold more active than ery-
thromycin against the bacteria. In addition to the role of the dendrimer
in increasing the aqueous solubility of erythromycin, the antibacterial
activity of the nanodendrimer conjugates can be due to the electrostatic
interactions between positively charged the erythromycin-conjugated
nanodendrimer and the negatively charged bacterial membrane that
resulting in the increase of membrane permeability and bacterial lysis
(da Silva Santos et al., 2016; Madaan et al., 2014). Noteworthy, it is the
ﬁrst time that these nanodendrimer are used for erythromycin delivery
and showed signiﬁcant eﬀects in facilitation of delivering the drug such
as erythromycin through the bacterial cell wall. Several studies have
investigated the antibacterial activity of various dendrimers and drug-
conjugated dendrimers. Lopez et al. studied the antibacterial activity of
a series of amino-terminated poly(amidoamine) (PAMAM) dendrimers
modiﬁed with PEG. The results showed that PEGylation of the den-
drimers decreased their antibacterial activities. This reduction in anti-
bacterial activity was likely due to the decrease in the number of pro-
tonated amino groups and shielding of the positive charges by the PEG
chains, thus decreasing the electrostatic interactions of the dendrimers
with the negatively-charged (Lopez et al., 2009). In another study, the
use of PEGylated poly (propylene imine) (PPI) dendritic architecture for
the delivery ciproﬂoxacin resistant bacterial strains was studied. The
study showed that the ciproﬂoxacin loaded dendrimer has signiﬁcant
antibacterial activity than the plain PPI dendrimer (Karthikeyan et al.,
2012). Contrary to our study, in the study of performed by Bosnjakovic
and colleagues (Bosnjakovic et al., 2011), the antibacterial activity of
the poly(amidoamine) dendrimer-erythromycin conjugates against S.
aureus was comparable to free drug. They showed that this may be
because the gram-positive S. aureus has a thick cell wall, and the neutral
dendrimer may not provide a signiﬁcant intracellular transport ad-
vantage to the free drug.
Overall, the present study indicated that the erythromycin-con-
jugated nanodendrimers as a biocompatible compound have a high
drug payload, improve the solubility of the drug, and could lead to
improved antibacterial activity. Our study results encourage further
investigation of the potential of anionic drug-conjugated nanoden-
drimer as a new class of antibacterial agents that may be less likely to
induce bacterial resistance than conventional antibiotics.
5. Conclusion
In this study, the erythromycin-conjugated nanodendrimers showed
signiﬁcantly more antibacterial activity than erythromycin against
Gram positive and -negative bacteria. These nanodendrimers have a
high drug payload and potential of passing through biologic membrane
such as the bacterial cell wall. Thus linear-globular nanodendrimers
could be a promising drug delivery system in the treatment of bacterial
infection.
Acknowledgement
This research was supported by Islamic Azad University, Qom, Iran.
The authors would like to express their deepest gratitude to the mi-
crobiology laboratory staﬀ of Kashan University of Medical Sciences,
Kashan, Iran.
References
Abbasi, E., Aval, S.F., Akbarzadeh, A., Milani, M., Nasrabadi, H.T., Joo, S.W.,
Hanifehpour, Y., Nejati-Koshki, K., Pashaei-Asl, R., 2014. Dendrimers: synthesis,
applications, and properties. Nanoscale Res. Lett. 9, 247.
Akram, M., 2014. Citric acid cycle and role of its intermediates in metabolism. Cell
Biochem. Biophys. 68, 475–478.
Authimoolam, S.P., Dziubla, T.D., 2016. Biopolymeric mucin and synthetic polymer
analogs: their structure, function and role in biomedical applications. Polymer 8, 71.
Biswas, A.K., Islam, M.R., Choudhury, Z.S., Mostafa, A., Kadir, M.F., 2014.
Nanotechnology based approaches in cancer therapeutics. Adv. Nat. Sci. Nanosci.
Nanotechnol. 5, 043001.
Bosnjakovic, A., Mishra, M.K., Ren, W., Kurtoglu, Y.E., Shi, T., Fan, D., Kannan, R.M.,
2011. Poly (amidoamine) dendrimer-erythromycin conjugates for drug delivery to
macrophages involved in periprosthetic inﬂammation. Nanomedicine 7, 284–294.
Charles, S., Vasanthan, N., Kwon, D., Sekosan, G., Ghosh, S., 2012. Surface modiﬁcation
Table 1
MIC and MBC values of erythromycin and the erythromycin-conjugated nano-
dendrimer.
Bacteria Erythromycin Erythromycin-conjugated
nanodendrimer
MIC (μg/
mL)
MBC (μg/
mL)
MIC (μg/mL) MBC (μg/mL)
P. aeruginosa ATCC
27853
128 256 32 64
S. aureus ATCC 29213 16 32 8 16
S. epidermidis ATCC
12228
128 256 16 16
S. saprophyticus ATCC
15305
0.25 1 0.125 0.25
MIC: Minimum Inhibitory Concentration; MBC: Minimum Bactericidal
Concentration.
F. Fallah et al. European Journal of Pharmaceutical Sciences 123 (2018) 321–326
325
of poly(amidoamine) (PAMAM) dendrimer as antimicrobial agents. Tetrahedron Lett.
53, 6670–6675.
Chatterjee, D.K., Fong, L.S., Zhang, Y., 2008. Nanoparticles in photodynamic therapy: an
emerging paradigm. Adv. Drug Deliv. Rev. 60, 1627–1637.
Ghosh, A., Das, S., Dasgupta, R., 2018. Knowledge, attitude and practices about anti-
microbial resistance and appropriate use of antimicrobial agents among the MBBS
students of a medical college hospital in eastern India. Int. J. Basic. Clin. Pharmacol.
7, 370–374.
Henschler, D., 1994. Toxicity of chlorinated organic compounds: eﬀects of the in-
troduction of chlorine in organic molecules. Angew. Chem. Int. Ed. 33, 1920–1935.
Jain, N.K., Asthana, A., 2007. Dendritic systems in drug delivery applications. Expert
Opin. Drug Deliv. 4, 495–512.
Jelić, D., Antolović, R., 2016. From erythromycin to azithromycin and new potential ri-
bosome-binding antimicrobials. Antibiotics 5, 29.
Karthikeyan, R., Karempudi, B., Rasheed, S., Vijayaraj, P., 2012. Dendritic architechture
for the delivery of antibacterial agent against resistant producing strains. Cent. Eur. J.
Exp. Biol. 1, 45–48.
Lopez, A.I., Reins, R.Y., McDermott, A.M., Trautner, B.W., Cai, C., 2009. Antibacterial
activity and cytotoxicity of PEGylated poly (amidoamine) dendrimers. Mol. BioSyst.
5, 1148–1156.
Madaan, K., Kumar, S., Poonia, N., Lather, V., Pandita, D., 2014. Dendrimers in drug
delivery and targeting: drug-dendrimer interactions and toxicity issues. J. Pharm.
Bioallied. Sci. 6, 139.
Moritz, M., Geszke-Moritz, M., 2013. The newest achievements in synthesis,
immobilization and practical applications of antibacterial nanoparticles. Chem. Eng.
J. 228, 596–613.
Namazi, H., Adeli, M., 2003. Novel linear–globular thermoreversible hydrogel ABA type
copolymers from dendritic citric acid as the A blocks and poly (ethyleneglycol) as the
B block. Eur. Polym. J. 39, 1491–1500.
da Silva Santos, S., Igne Ferreira, E., Giarolla, J., 2016. Dendrimer prodrugs. Molecules
21, 686.
Strydom, S.J., Rose, W.E., Otto, D.P., Liebenberg, W., De Villiers, M.M., 2013. Poly
(amidoamine) dendrimer-mediated synthesis and stabilization of silver sulfonamide
nanoparticles with increased antibacterial activity. Nanomedicine: NBM 9, 85–93.
Tabatabaei, S.R., Rahbar, M., Alam, A.N., Fallah, F., Hashemi, A., Youseﬁ, M., Houri, H.,
Karimi, A., 2017. Detection of pbp2b gene and antimicrobial susceptibility pattern of
Streptococcus pneumoniae isolates in Tehran hospitals, Iran. Arch. Pediatr. Infect.
Dis. 5.
Tanwar, J., Das, S., Fatima, Z., Hameed, S., 2014. Multidrug resistance: an emerging
crisis. Int. Perspect. Infect. Dis. 2014.
Tulu, M., Aghatabay, N.M., Senel, M., Dizman, C., Parali, T., Dulger, B., 2009. Synthesis,
characterization and antimicrobial activity of water soluble dendritic macro-
molecules. Eur. J. Med. Chem. 44, 1093–1099.
Twibanire, J.D.A.K., Grindley, T.B., 2014. Polyester dendrimers: smart carriers for drug
delivery. Polymer 6, 179–213.
Wayne, P.A., 2004. Clinical and laboratory standards institute. Performance standards for
antimicrobial susceptibility testing. In: Twenty-Fourth Informational Supplement.
CLSI Document M100-S24.
F. Fallah et al. European Journal of Pharmaceutical Sciences 123 (2018) 321–326
326
